Shattuck Labs Announces Participation in Needham’s 20th Annual Healthcare Conference

Rhea-AI Summary

Shattuck Labs, Inc. (NASDAQ: STTK) will participate in the 20th Annual Needham Healthcare Conference held virtually from April 12-15, 2021. CEO Taylor Schreiber, M.D., Ph.D., and CFO Andrew Neill will present on April 14, 2021, at 11:00 a.m. EST in a fireside chat format. The event can be accessed through a live webcast, with a replay available for up to 90 days. Shattuck Labs focuses on developing bi-functional fusion proteins aimed at treating cancer and autoimmune diseases, with its lead candidate SL-172154 currently in a Phase 1 trial.

Positive

• Participation in a prominent healthcare conference may enhance visibility and investor interest.
• Showcasing innovative bi-functional fusion proteins could attract potential partnerships.

Negative

• None.

AUSTIN, TX and DURHAM, NC, April 06, 2021 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced it will participate in Needham’s 20th Annual Healthcare Conference being held virtually April 12-15, 2021.

Presentation Details
Conference: 20th Annual Needham Healthcare Conference
Format: Fireside chat with covering analyst, Chad Messer, Ph.D.
Presenters: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive Officer and Andrew Neill, Shattuck’s Chief Financial Officer
Date: April 14, 2021
Time: 11:00 a.m. EST
Webcast Link: Available Here

A live webcast will be available on the Events & Presentations section of the Company’s website. A replay of the webcast will be archived for up to 90 days following the presentation date.

About Shattuck Labs, Inc.
Shattuck is a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Compounds derived from Shattuck’s proprietary Agonist Redirected Checkpoint, ARC^®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic. The company’s lead wholly owned program, SL-172154 (SIRPα-Fc-CD40L), which is designed to block the CD47 immune checkpoint and simultaneously agonize the CD40 pathway, is being evaluated in a Phase 1 trial. A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals. Additionally, the company is advancing a proprietary Gamma Delta T Cell Engager, GADLEN™, platform, which is designed to bridge gamma delta T cells to tumor antigens for the treatment of patients with cancer. Shattuck has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.

Investor Contact:
Conor Richardson
Senior Director, Finance & Investor Relations
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com

Media Contact:
Stephanie Ascher
Managing Director
Stern Investor Relations, Inc.
Stephanie.ascher@sternir.com

FAQ

When is Shattuck Labs participating in the Needham Healthcare Conference?

Shattuck Labs will participate in the Needham Healthcare Conference from April 12-15, 2021, with their presentation on April 14 at 11:00 a.m. EST.

Who will present for Shattuck Labs at the Needham Healthcare Conference?

CEO Taylor Schreiber and CFO Andrew Neill will present for Shattuck Labs at the conference.

What is Shattuck Labs' lead program currently in trials?

Shattuck Labs' lead program, SL-172154, is designed to block the CD47 immune checkpoint and is currently in a Phase 1 trial.

Where can I watch the Shattuck Labs presentation from the Needham Healthcare Conference?

The presentation will be available via a live webcast, with a replay archived for up to 90 days on the company's website.